AGE logo

AgeX Therapeutics (AGE) Stock

Profile

Full Name:

AgeX Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 November 2018

Indexes:

Not included

Website:

http://www.agexinc.com

Description:

As of March 26, 2024, AgeX Therapeutics, Inc. was acquired by Serina Therapeutics, Inc., in a reverse merger transaction. AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$142.00 K(+317.65% YoY)

Annual EPS

-$482.53(-4800.00% YoY)

PE Ratio

-

Annual ROE

-270.67%

Annual Debt To Equity

0.80

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 31, 2024

Recent annual earnings:

Mar 31, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Mar 15, 2024

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with AGE included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$196.43
AGE price is currently at an all-time high

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

-60.66%
AGE annual revenue is down -60.66% over the past 3 years

Annual Net Income 3-Year Change

-36.24%
AGE annual net profit is down -36.24% over the past 3 years

Annual EPS 3-Year Change

-4631.03%
AGE annual earnings per share is down -4631.03% over the past 3 years

Annual Gross Profit

$102.00 K
AGE annual gross profit is $102.00 thousand

Annual Operating Profit

-$9.96 M
AGE annual operaing income is -$9.96 million

Annual Operating Profit 3-Year Change

+1.39%
AGE annual operaing income is up +1.39% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-270.67%
AGE annual return on equity is -270.67%

Annual ROA

-123.72%
AGE annual return on assets is -123.72%

Annual EBIT

-$9.91 M
AGE annual earnings before interest & taxes is -$9.91 million

Annual EBITDA

-$9.82 M
AGE annual earnings before interest, taxes, depreciation & amortization is -$9.82 million

Annual Interest Coverage Ratio

-2.02
AGE annual interest coverage ratio is -2.02

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Current Ratio

0.13
AGE annual current ratio is 0.13

Annual Total Assets

$11.96 M
AGE annual total assets is $11.96 million

Annual Current Assets

$754.00 K
AGE annual total current assets is $754.00 thousand

Annual Total Liabilities

$6.61 M
AGE annual total liabilities is $6.61 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+0.22%
AGE annual cash flow from operations is up +0.22% over the past 3 years

Annual CFI 3-Year Change

-49900%
AGE annual cash flow from investing activities is down -49900% over the past 3 years

Annual CFF 3-Year Change

+193.57%
AGE annual cash flow from financing activities is up +193.57% over the past 3 years

Annual FCF

-$7.80 M
AGE annual free cash flow is -$7.80 million

Annual FCF 3-Year Change

+0.47%
AGE annual free cash flow is up +0.47% over the past 3 years

Institutional Ownership

Similar stocks

DiagnaMed Expands with Drug and Clinical Research AI Platform
DiagnaMed Expands with Drug and Clinical Research AI Platform
DiagnaMed Expands with Drug and Clinical Research AI Platform
AGE
globenewswire.com21 August 2024

Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development and discovering potential novel treatments for neurological, psychiatric and infectious diseases TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, announces it is expanding the use of its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”) through leveraging its electroencephalograph (“EEG”) data from research studies and future data collection, and applying it to build a potential drug discovery and clinical research AI platform. EEG provides a real-time readout of brain-wave activity in different brain regions and can measure a drug effect on the brain.

Serina Therapeutics merger promises to reboot ‘human longevity' firm AgeX
Serina Therapeutics merger promises to reboot ‘human longevity' firm AgeX
Serina Therapeutics merger promises to reboot ‘human longevity' firm AgeX
AGE
Proactive Investors30 August 2023

Privately-owned Serina Therapeutics Inc is being merged into AgeX Therapeutics (NYSE:AGE) in a move that will reboot the Nasdaq ‘human longevity' stock, into an immunology and gene therapy firm seeking a treatment of Parkinson's disease. Holders of Serina, a specialist in ‘small molecule' central nervous system drug discovery, will own 75% of the combined company's equity as a result of the ‘reverse merger' transaction.

FAQ

  • What is the primary business of AgeX Therapeutics?
  • What is the ticker symbol for AgeX Therapeutics?
  • Does AgeX Therapeutics pay dividends?
  • What sector is AgeX Therapeutics in?
  • What industry is AgeX Therapeutics in?
  • What country is AgeX Therapeutics based in?
  • When did AgeX Therapeutics go public?
  • Is AgeX Therapeutics in the S&P 500?
  • Is AgeX Therapeutics in the NASDAQ 100?
  • Is AgeX Therapeutics in the Dow Jones?
  • When was AgeX Therapeutics's last earnings report?
  • When does AgeX Therapeutics report earnings?

What is the primary business of AgeX Therapeutics?

As of March 26, 2024, AgeX Therapeutics, Inc. was acquired by Serina Therapeutics, Inc., in a reverse merger transaction. AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

What is the ticker symbol for AgeX Therapeutics?

The ticker symbol for AgeX Therapeutics is NYSE American:AGE

Does AgeX Therapeutics pay dividends?

No, AgeX Therapeutics does not pay dividends

What sector is AgeX Therapeutics in?

AgeX Therapeutics is in the Healthcare sector

What industry is AgeX Therapeutics in?

AgeX Therapeutics is in the Biotechnology industry

What country is AgeX Therapeutics based in?

AgeX Therapeutics is headquartered in United States

When did AgeX Therapeutics go public?

AgeX Therapeutics's initial public offering (IPO) was on 29 November 2018

Is AgeX Therapeutics in the S&P 500?

No, AgeX Therapeutics is not included in the S&P 500 index

Is AgeX Therapeutics in the NASDAQ 100?

No, AgeX Therapeutics is not included in the NASDAQ 100 index

Is AgeX Therapeutics in the Dow Jones?

No, AgeX Therapeutics is not included in the Dow Jones index

When was AgeX Therapeutics's last earnings report?

AgeX Therapeutics's most recent earnings report was on 31 May 2024

When does AgeX Therapeutics report earnings?

The date for AgeX Therapeutics's next earnings report has not been announced yet